BBNX
Beta Bionics, Inc.
NASDAQ · Healthcare · Medical - Equipment & Services · US
$21.89
+2.15%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$21.38
From 52W high−31.57%
Volume1.48M
Market cap$984.82M
P/E (TTM)—
P/S (TTM)8.3x
Div yield—
Key dataSep 18, 2026
Open
$21.38
From 52W high
−31.57%
Volume
1.48M
Market cap
$984.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.3x
P/E (TTM)
—
RSI (14)
63.8
MomentumView details →
1D Return
+2.15%
YTD Return
−29.13%
SummaryUpdated Jun 1, 2026
Beta Bionics, Inc. (NASDAQ:BBNX) is a commercial-stage medical device company founded in 2015 and based in Irvine, California. The company specializes in developing automated insulin delivery systems for people with diabetes, with its flagship product being the <b>iLet Bionic Pancreas</b>. Beta Bionics went public on January 30, 2025, representing a significant milestone for the company as it transitions from development to commercial expansion in the diabetes management market.
Similar companies
Latest newsMore news →
Beta Bionics, Inc. (BBNX) shares surged 15.3% in the prior trading session on above-average trading volume.3d agoBeta Bionics priced a public offering of 7,652,175 common shares at $17.25 per share, plus 1,043,484 pre-funded warrants at $17.2499 each, to raise about $150 million before expenses, expected to close around September 17.4d agoBeta Bionics, Inc. announced a proposed underwritten public offering of $125.0 million of its common stock, with a 30-day underwriter option for up to an additional $18.75 million of shares.5d ago